Lumanity Executive and Leadership Team

Andrew Dreyfus, the President & Chief Executive Officer at Lumanity, directs the overarching corporate strategy and operational execution. Dreyfus guides the organization's mission to accelerate and optimize access to medical advances by applying incisive thinking and decisive action to complex situations. This leadership role involves translating data and information into real-world insights and evidence that power successful commercialization. Overseeing global operations, Andrew Dreyfus ensures alignment with Lumanity's commitment to empowering patients, providers, payers, and regulators worldwide. The Chief Executive Officer's focus remains on driving transformative outcomes and fostering sustainable success in the market through strategic decision-making and cross-functional collaboration across Lumanity's extensive network.

Rebecca Hyde, the Chief Operating Officer and Global Practice Lead, Value Access and Outcomes at Lumanity, orchestrates the company's global operational framework and leads the critical Value Access and Outcomes practice. Hyde ensures the seamless execution of Lumanity's mission to transform data into real-world insights, specifically focusing on demonstrating product value and optimizing patient access. This role involves managing the integration of medical, commercial, and regulatory expertise across diverse geographies, including North America, the United Kingdom, Europe, and Asia. Rebecca Hyde drives the development of evidence generation strategies that support successful commercialization and empower stakeholders to take timely action. The Chief Operating Officer's oversight extends to fostering collaboration among Lumanity's 1,200+ experts to deliver transformative outcomes for pharmaceutical and biotech clients.

Marissa Poli, the President at Lumanity, drives strategic initiatives and operational excellence across key business segments. Poli's leadership focuses on translating Lumanity's deep experience in medical, commercial, and regulatory affairs into actionable insights that accelerate market access for medical advances. This executive role involves fostering a culture of decisive action and incisive thinking to navigate complex market dynamics and deliver transformative outcomes for clients. Marissa Poli ensures that Lumanity's global teams are aligned with the company's core mission of empowering patients, providers, payers, and regulators through robust real-world evidence. The President's purview includes enhancing the company's capabilities in demonstrating product value and positioning innovations for sustainable market success.

Amber Gilbert, the Global President, Market Access at Lumanity, spearheads the company's strategic approach to ensuring products reach patients effectively and at a value-reflective price. Gilbert directs the generation and application of real-world evidence to demonstrate product value, a critical component of Lumanity's mission. This leadership position involves translating complex scientific data into compelling narratives that resonate with global stakeholders, including payers and regulators. Amber Gilbert oversees the development and execution of market access strategies that position pharmaceutical and biotech products for sustainable commercial success. The Global President's focus is on enabling decisive action by clients through comprehensive market understanding and evidence-based solutions across North America, Europe, and Asia.

Juliet Munakata, the Global President, HEOR (Health Economics and Outcomes Research) at Lumanity, leads the critical function of generating and communicating the evidence required to demonstrate product value. Munakata directs the strategic development of health economic models and outcomes research studies that underpin successful commercialization efforts. This role is pivotal in translating scientific advancements into compelling data that supports payer submissions and regulatory approvals worldwide. Juliet Munakata ensures that Lumanity's HEOR experts provide incisive thinking and decisive action, transforming complex data into real-world insights. The Global President's leadership empowers clients to articulate the value of their innovations and secure optimal market positioning, contributing directly to patient access.

Christopher Evans, the President Patient-Centered Outcomes at Lumanity, drives the strategic focus on understanding and demonstrating the value of medical advances from the patient's perspective. Evans leads initiatives to generate real-world evidence that highlights patient impact, preferences, and outcomes, crucial for payers and providers. This executive role involves integrating patient insights into commercialization strategies, ensuring that products meet the needs of those they are intended to serve. Christopher Evans oversees the development of frameworks that empower patients, providers, and payers to take timely and informed action based on comprehensive outcome data. The President's leadership ensures Lumanity's work directly translates scientific data into tangible benefits for patients globally.

John Howley, the President, Communications (US) at Lumanity, directs the strategic communication efforts within the United States, ensuring clear and compelling articulation of product value and company mission. Howley oversees the translation of complex scientific and commercial data into impactful narratives that resonate with diverse stakeholders, including patients, providers, and payers. This leadership role is essential for demonstrating the value of medical advances and supporting successful commercialization. John Howley ensures that Lumanity's communication strategies empower decisive action by aligning stakeholders around real-world insights and evidence. The President's focus is on building strong relationships and fostering understanding through expert communication across the US market.

Stephen Weisman, the Global President at Lumanity, drives strategic growth and operational effectiveness across the company's international operations. Weisman's leadership focuses on applying incisive thinking to complex market challenges, ensuring Lumanity delivers transformative outcomes that accelerate access to medical advances. This role involves overseeing the generation and application of real-world evidence to demonstrate product value and support successful commercialization globally. Stephen Weisman empowers clients by translating science and data into compelling product narratives relevant to stakeholders worldwide. The Global President's commitment is to enable commercial decisions that position products for sustainable success, turning aspiration into reality for pharmaceutical and biotech partners.

Nicole Ramocki, the Global President, Market Access at Lumanity, leads the strategic imperative to ensure optimal patient access to medical innovations through value demonstration and effective market positioning. Ramocki directs the generation of robust real-world evidence, translating complex data into compelling insights that support payer submissions and regulatory approvals worldwide. This executive function is critical for articulating the value of products at a price reflective of their benefits. Nicole Ramocki oversees the development and implementation of market access strategies that empower stakeholders to take decisive action, fostering sustainable commercial success. The Global President's expertise ensures Lumanity's clients navigate global markets effectively, bringing vital treatments to patients.